FDA Purple Book · Reference family
donislecel-jujn (Lantidra)
donislecel-jujn is an FDA-licensed reference biologic from CellTrans Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
351(a)BLA 125734
Lantidra donislecel-jujn
CellTrans Inc.
- Approved
- Jun 28, 2023
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for donislecel-jujn, in chronological order.
Reference approval
Approval date of the reference donislecel-jujn product.
3 yr ago
Frequently asked questions
Are there biosimilars approved for donislecel-jujn (Lantidra)?
No 351(k) biosimilars or interchangeable biosimilars referencing donislecel-jujn are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.